2017 AACC Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research
Dr. Katzmann retired from the Mayo Clinic in 2014, where he was associate professor of laboratory medicine and pathology, assistant professor of microbiology, and
co-director of the immunology laboratory. He joined the Mayo Clinic in 1976 and spent almost his entire career working in the field of multiple myeloma and related monoclonal gammopathies. He played a key role in discovering and establishing the best diagnostic and prognostic markers for monoclonal gammopathies. He published some of the earliest papers on the role of beta-2 microglobulin as a prognostic marker for both myeloma and AL amyloidosis. His flow cytometry work established the value of plasma cell labeling as a prognostic factor in patients with newly diagnosed multiple myeloma. He led the way in establishing the role of
free light chain measurements as a diagnostic marker, as a risk factor for the progression of monoclonal gammopathies of undetermined significance, and
as a prognostic factor. These contributions are still part of clinical practice today.
Dr. Katzmann has also made significant contributions to our understanding of the laboratory instrumentation for detecting monoclonal gammopathies. His studies have demonstrated differences between nephelometry, protein electrophoresis, and capillary electrophoresis. He established the Mayo Clinic’s flow cytometry and hybridoma laboratories. Dr. Katzmann’s contributions and publications are recognized internationally, and include more than 200 peer-reviewed articles, 25 book chapters, and 200 abstracts for national and international conferences. He has also contributed significantly to the education of others in this field, hosting several short courses at AACC annual meetings as well as at numerous international conferences, where he has trained hundreds of clinical chemists.